enGene Therapeutics Inc. (ENGN)
| Market Cap | 99.81M -49.7% |
| Revenue (ttm) | n/a |
| Net Income | -122.44M |
| EPS | -2.22 |
| Shares Out | 66.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,659,507 |
| Open | 1.510 |
| Previous Close | 1.500 |
| Day's Range | 1.445 - 1.580 |
| 52-Week Range | 1.445 - 12.250 |
| Beta | -0.01 |
| Analysts | Buy |
| Price Target | 14.19 (+852.35%) |
| Earnings Date | Jun 11, 2026 |
About ENGN
enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ENGN stock is "Buy." The 12-month stock price target is $14.19, which is an increase of 852.35% from the latest price.
News
Leerink downgraded enGene to Market Perform following LEGEND update
As previously reported, Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a price target of $2, down from $19, following the “disappointing” LEGEND update as key debates around…
enGene downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded enGene (ENGN) to Perform from Outperform. The firm views updated interim data from the pivotal LEGEND cohort in BCG-unresponsive NMIBC as disappointing, and while the approval d...
enGene downgraded to Market Perform from Outperform at Leerink
Leerink downgraded enGene (ENGN) to Market Perform from Outperform with a $2 price target
enGene downgraded to Outperform from Strong Buy at Raymond James
Raymond James downgraded enGene (ENGN) to Outperform from Strong Buy with a price target of $4, down from $27, after the company announced interim results from the pivotal cohort of…
enGene downgraded to Neutral from Buy at Guggenheim
Guggenheim yesterday downgraded enGene (ENGN) to Neutral from Buy without a price target after the company announced interim results from the pivotal cohort of LEGEND, evaluating detalimogene in BCG-u...
enGene downgraded to Neutral from Overweight at Piper Sandler
Piper Sandler analyst Allison Bratzel downgraded enGene (ENGN) to Neutral from Overweight with a price target of $4, down from $7, after the company announced interim results from the pivotal…
enGene downgraded to Market Perform from Outperform at Citizens
Citizens downgraded enGene (ENGN) to Market Perform from Outperform without a price target The company’s updated results from the pivotal LEGEND study “worsened significantly,” the analyst tells inves...
enGene downgraded to Equal Weight from Overweight at Wells Fargo
Wells Fargo downgraded enGene (ENGN) to Equal Weight from Overweight with a price target of $2, down from $25. The company’s efficacy data for detalimogene is weaker than the last…
enGene downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Judah Frommer downgraded enGene (ENGN) to Equal Weight from Overweight without a price target after the company announced interim results from the pivotal cohort of LEGEND, eval...
enGene downgraded to Neutral from Buy at Guggenheim
Guggenheim downgraded enGene (ENGN) to Neutral from Buy.
enGene Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of enGene Therapeutics Inc. (NASDAQ: ENGN). The investigation focuses on enGen...
enGene announces updated interim results from LEGEND cohort
enGene (ENGN) Therapeutics reported additional interim results from the pivotal cohort of its ongoing, Phase 2 LEGEND trial of detalimogene voraplasmid in high-risk, Bacillus Calmette-Guerin-unrespons...
enGene Therapeutics Transcript: Study result
LEGEND phase II pivotal cohort data show detalimogene achieved a 54% CR at any time and 43% at six months, with strong tolerability and low discontinuation rates. Lower response rates in a recent subgroup are under further analysis. A new surfactant bladder rinse cohort is enrolling, and mature data plus FDA engagement are expected in the second half of the year.
enGene Announces Updated Interim Results From LEGEND Pivotal Cohort
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (Nasdaq: ENGN or “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today reported additional interim resul...
enGene initiated with a Buy at WBB Securities
WBB Securities initiated coverage of enGene (ENGN) with a Buy rating and $21.50 price target
enGene announces name change to enGene Therapeutics
enGene (ENGN) will change its corporate name to “enGene Therapeutics Inc.” effective April 8. The Company elected to change its corporate name to reflect the near-term transition to a commercial…
enGene Announces Name Change to enGene Therapeutics Inc.
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Therapeutics Inc. (formerly, enGene Holdings Inc.) (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, is pleas...
Three new option listings and three option delistings on April 6th
New option listings for April 6th include enGene Holdings Inc (ENGN), Keel Infrastructure Corp. (KEEL), and NovaBay Pharmaceuticals Inc (SDEV). Option delistings effective April 6th include NovaBay (N...
enGene price target lowered to $9 from $10 at UBS
UBS analyst David Dai lowered the firm’s price target on enGene (ENGN) to $9 from $10 and keeps a Neutral rating on the shares following the fiscal Q1 report. The…
enGene Therapeutics Transcript: The Citizens Life Sciences Conference 2026
NMIBC treatment is shifting from radical surgery to more tolerable, effective therapies, with detalimogene showing strong efficacy and ease of use for community urologists. Key data updates are expected in Q2 and later this year, supporting a potential 2027 approval.
enGene price target lowered to $30 from $33 at Oppenheimer
Oppenheimer lowered the firm’s price target on enGene (ENGN) to $30 from $33 and keeps an Outperform rating on the shares. The firm notes the company announced that it plans…
enGene Therapeutics Transcript: Barclays 28th Annual Global Healthcare Conference
Detalimogene, a non-viral gene therapy for NMIBC, is advancing through pivotal trials with strong regulatory support and a focus on community urologists. The product's ease of use, competitive efficacy, and favorable tolerability are expected to drive adoption as the market shifts toward sequencing therapies.
enGene price target lowered to $27 from $30 at Guggenheim
Guggenheim analyst Michael Schmidt lowered the firm’s price target on enGene (ENGN) to $27 from $30 and keeps a Buy rating on the shares after the company reported Q1 earnings…
enGene Therapeutics Transcript: Leerink Global Healthcare Conference 2026
Major protocol amendments and improved execution have driven higher response rates in the pivotal cohort, with 12-month data expected later this year. Regulatory engagement is strong, aided by RMAT and CDRP designations, and the product is positioned for broad adoption in community urology practices due to its ease of use and favorable economics.
enGene Reports First Quarter 2026 Financial Results and Provides Business Update
BOSTON & MONTREAL--(BUSINESS WIRE)--enGene Holdings Inc. (Nasdaq: ENGN, “enGene” or the “Company”), a clinical-stage, non-viral genetic medicines company, today announced its financial results for the...